ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 244 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,149,303 | +2.5% | 275,079 | +12.8% | 0.00% | 0.0% |
| Q1 2024 | $6,974,196 | +1.0% | 243,853 | +8.0% | 0.00% | -33.3% |
| Q4 2023 | $6,907,185 | +13.3% | 225,725 | -0.5% | 0.00% | 0.0% |
| Q3 2023 | $6,094,009 | -26.1% | 226,796 | -2.0% | 0.00% | 0.0% |
| Q2 2023 | $8,249,763 | +7.1% | 231,345 | -23.7% | 0.00% | 0.0% |
| Q1 2023 | $7,700,924 | -92.7% | 303,186 | -88.3% | 0.00% | -93.6% |
| Q4 2022 | $104,835,148 | +28.6% | 2,584,693 | +4.8% | 0.05% | +20.5% |
| Q3 2022 | $81,536,000 | -17.2% | 2,467,060 | -11.8% | 0.04% | -13.3% |
| Q2 2022 | $98,522,000 | -22.3% | 2,798,134 | +1.5% | 0.04% | -8.2% |
| Q1 2022 | $126,764,000 | -22.4% | 2,756,331 | +11.8% | 0.05% | -15.5% |
| Q4 2021 | $163,397,000 | +169.7% | 2,464,511 | +154.0% | 0.06% | +141.7% |
| Q3 2021 | $60,575,000 | -34.5% | 970,293 | -13.1% | 0.02% | -35.1% |
| Q2 2021 | $92,500,000 | +30.9% | 1,116,880 | +4.8% | 0.04% | +19.4% |
| Q1 2021 | $70,686,000 | +201.1% | 1,065,997 | +248.4% | 0.03% | +181.8% |
| Q4 2020 | $23,479,000 | +71.2% | 305,992 | -3.9% | 0.01% | +57.1% |
| Q3 2020 | $13,717,000 | -10.6% | 318,552 | -10.3% | 0.01% | -22.2% |
| Q2 2020 | $15,344,000 | +65.0% | 355,270 | +9.9% | 0.01% | +28.6% |
| Q1 2020 | $9,302,000 | -55.6% | 323,310 | -2.1% | 0.01% | -41.7% |
| Q4 2019 | $20,940,000 | +201.7% | 330,120 | +34.0% | 0.01% | +200.0% |
| Q3 2019 | $6,940,000 | -1.7% | 246,270 | -7.5% | 0.00% | 0.0% |
| Q2 2019 | $7,059,000 | +245.4% | 266,370 | +139.2% | 0.00% | +300.0% |
| Q1 2019 | $2,044,000 | +26.9% | 111,372 | -14.1% | 0.00% | 0.0% |
| Q4 2018 | $1,611,000 | -35.2% | 129,700 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $2,486,000 | +77.4% | 129,700 | +25.9% | 0.00% | +100.0% |
| Q2 2018 | $1,401,000 | +872.9% | 103,000 | +32.2% | 0.00% | – |
| Q1 2017 | $144,000 | +13.4% | 77,900 | -5.1% | 0.00% | – |
| Q4 2016 | $127,000 | -75.8% | 82,100 | +15.1% | 0.00% | – |
| Q3 2016 | $524,000 | +38.3% | 71,300 | 0.0% | 0.00% | – |
| Q2 2016 | $379,000 | – | 71,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $93,815,000 | 51.06% |
| Aquilo Capital Management, LLC | 436,514 | $12,559,000 | 4.90% |
| Vivo Capital, LLC | 768,674 | $22,115,000 | 2.00% |
| ACUTA CAPITAL PARTNERS, LLC | 109,700 | $3,156,000 | 1.53% |
| Prosight Management, LP | 104,737 | $3,013,000 | 1.41% |
| Capital Impact Advisors, LLC | 84,537 | $2,432,000 | 1.02% |
| Artal Group S.A. | 600,000 | $17,262,000 | 0.73% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 62,000 | $1,784,000 | 0.48% |
| Quantitative Investment Management, LLC | 150,401 | $4,327,000 | 0.47% |
| OAK RIDGE INVESTMENTS LLC | 131,502 | $3,784,000 | 0.39% |